- Home
- BB vs CELC Comparison
BB vs CELC Comparison
Compare BB & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BB
- CELC
- Stock Information
- Founded
- BB 1984
- CELC 2011
- Country
- BB Canada
- CELC United States
- Employees
- BB N/A
- CELC N/A
- Industry
- BB
- CELC Medical Specialities
- Sector
- BB
- CELC Health Care
- Exchange
- BB Nasdaq
- CELC Nasdaq
- Market Cap
- BB 2.8B
- CELC 3.1B
- IPO Year
- BB 1997
- CELC 2017
- Fundamental
- Price
- BB $4.16
- CELC $94.58
- Analyst Decision
- BB Hold
- CELC Strong Buy
- Analyst Count
- BB 6
- CELC 7
- Target Price
- BB $4.98
- CELC $95.29
- AVG Volume (30 Days)
- BB 8.7M
- CELC 916.2K
- Earning Date
- BB 12-18-2025
- CELC 11-12-2025
- Dividend Yield
- BB N/A
- CELC N/A
- EPS Growth
- BB N/A
- CELC N/A
- EPS
- BB N/A
- CELC N/A
- Revenue
- BB $536,600,000.00
- CELC N/A
- Revenue This Year
- BB $2.43
- CELC N/A
- Revenue Next Year
- BB $7.36
- CELC N/A
- P/E Ratio
- BB N/A
- CELC N/A
- Revenue Growth
- BB N/A
- CELC N/A
- 52 Week Low
- BB $2.29
- CELC $7.58
- 52 Week High
- BB $6.24
- CELC $98.43
- Technical
- Relative Strength Index (RSI)
- BB 35.76
- CELC 78.51
- Support Level
- BB $4.10
- CELC $86.56
- Resistance Level
- BB $4.35
- CELC $96.10
- Average True Range (ATR)
- BB 0.17
- CELC 4.80
- MACD
- BB -0.06
- CELC 0.95
- Stochastic Oscillator
- BB 5.42
- CELC 84.40
About BB BlackBerry Limited
BlackBerry, once known for being the world's largest smartphone manufacturer, is now exclusively a software provider with a stated goal of end-to-end secure communications for enterprises. The firm provides endpoint management and other secure communications software to enterprises, specializing in regulated industries like government and financial institutions. BlackBerry also has a sizable embedded software business primarily serving the automotive market, with some exposure to the industrial market.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.